Abiogen licenses RFB4 antibody from Cancers Research Technology Cancer Research Technology Limited.

The contract supersedes a earlier licence with Abiogen and will enable Abiogen to keep to utilize the RFB4 antibody, in combination with essential technology from the University of Texas Southwestern INFIRMARY at Dallas, to develop its pipeline therapeutics. Related StoriesMeat-rich diet may increase kidney cancer riskNew findings reveal association between colorectal cancer and melanoma drug treatmentStudy shows rare HER2 missense mutations usually do not spread breasts cancer on their ownOriginally developed by experts at the Royal Free Hospital School of Medicine in London, RFHSM assigned its ownership privileges in the RFB4 cell collection to Imperial Cancer Research Technology .Kaiser Family Foundation. Copyright 2008 Advisory Board Organization and Kaiser Family Basis. All rights reserved.

Allergies might be caused by a malfunction of the respiratory epithelium One reason behind the advancement of allergy could be malfunction of the respiratory epithelium, which allows allergens to bind to, enter and travel through the epithelium. Two tests by Finnish research groups on this subject have been released in two international biomedical journals Allergy lately, and Journal of Clinical and Allergy Immunology. Research on the mechanisms of allergy offers focused on the understanding of aberrant immunoresponses.